Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).
Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.
Business funding insights
BGF explains: initial public offerings (IPOs)
We explain what’s meant by an initial public offering (IPO), also known as listing or ‘going public’.
When to pursue debt refinancing and why
You may find that refinancing or renegotiating your business debts can put you in a stronger financial position. Look at…